In the past week, JAZZ stock has gone up by 4.36%, with a monthly gain of 7.45% and a quarterly surge of 12.00%. The volatility ratio for the week is 2.88%, and the volatility levels for the last 30 days are 2.44% for Jazz Pharmaceuticals plc The simple moving average for the last 20 days is 7.65% for JAZZ stock, with a simple moving average of 10.02% for the last 200 days.
Is It Worth Investing in Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Right Now?
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has a price-to-earnings ratio that is above its average at 17.90x. The stock has a 36-month beta value of 0.58. Opinions on the stock are mixed, with 12 analysts rating it as a “buy,” 8 as “overweight,” 5 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for JAZZ is 58.39M, and at present, short sellers hold a 6.15% of that float. On November 15, 2024, the average trading volume of JAZZ was 667.89K shares.
JAZZ) stock’s latest price update
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)’s stock price has plunge by -2.65relation to previous closing price of 127.65. Nevertheless, the company has seen a 4.36% surge in its stock price over the last five trading sessions. zacks.com reported 2024-11-14 that Investors need to pay close attention to Jazz (JAZZ) stock based on the movements in the options market lately.
Analysts’ Opinion of JAZZ
Many brokerage firms have already submitted their reports for JAZZ stocks, with Goldman repeating the rating for JAZZ by listing it as a “Buy.” The predicted price for JAZZ in the upcoming period, according to Goldman is $169 based on the research report published on June 05, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see JAZZ reach a price target of $160. The rating they have provided for JAZZ stocks is “Outperform” according to the report published on January 03rd, 2024.
UBS gave a rating of “Neutral” to JAZZ, setting the target price at $135 in the report published on November 27th of the previous year.
JAZZ Trading at 11.03% from the 50-Day Moving Average
After a stumble in the market that brought JAZZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.38% of loss for the given period.
Volatility was left at 2.44%, however, over the last 30 days, the volatility rate increased by 2.88%, as shares surge +8.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.65% upper at present.
During the last 5 trading sessions, JAZZ rose by +4.36%, which changed the moving average for the period of 200-days by +1.26% in comparison to the 20-day moving average, which settled at $115.44. In addition, Jazz Pharmaceuticals plc saw 1.03% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JAZZ starting from Patil Neena M, who sale 3,700 shares at the price of $123.41 back on Nov 08 ’24. After this action, Patil Neena M now owns 33,048 shares of Jazz Pharmaceuticals plc, valued at $456,617 using the latest closing price.
Patil Neena M, the Officer of Jazz Pharmaceuticals plc, proposed sale 3,700 shares at $123.41 during a trade that took place back on Nov 08 ’24, which means that Patil Neena M is holding shares at $456,632 based on the most recent closing price.
Stock Fundamentals for JAZZ
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.78 for the gross margin
The net margin for Jazz Pharmaceuticals plc stands at 0.12. The total capital return value is set at 0.07. Equity return is now at value 12.09, with 3.95 for asset returns.
Based on Jazz Pharmaceuticals plc (JAZZ), the company’s capital structure generated 0.59 points at debt to capital in total, while cash flow to debt ratio is standing at 0.19. The debt to equity ratio resting at 1.47. The interest coverage ratio of the stock is 2.67.
Currently, EBITDA for the company is 1.45 billion with net debt to EBITDA at 3.09. When we switch over and look at the enterprise to sales, we see a ratio of 2.87. The receivables turnover for the company is 5.52for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.26.
Conclusion
To sum up, Jazz Pharmaceuticals plc (JAZZ) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
